Invasive Bladder Urothelial Carcinoma
Oncology
Prevalence
61.0 / 100K
Incidence
18.0 / 100K/yr
3 drugs in development·3 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(2)
Phase 2(1)
| Drug | Company |
|---|---|
| Relatlimab | ENANTA PHARMACEUTICALS INC (ENTA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Invasive Bladder Urothelial Carcinoma?
BioSniper tracks 3 drugs in development for Invasive Bladder Urothelial Carcinoma across 3 companies.
How many clinical trials target Invasive Bladder Urothelial Carcinoma?
There are 1 clinical trial targeting Invasive Bladder Urothelial Carcinoma tracked by BioSniper.
What is the prevalence of Invasive Bladder Urothelial Carcinoma?
The estimated prevalence of Invasive Bladder Urothelial Carcinoma is approximately 61.0 per 100,000 population.
Deep-dive into Invasive Bladder Urothelial Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis